Given a question and a context passage, generate the answer having the word or phrase from the context passage. Here, the answer should be a shortest continous span from the passage.

Q: Context: In week 12, the Lions flew east for another battle of division leaders, this time with the AFC East's 8-2 New England Patriots. The Lions failed to score a touchdown for the second consecutive week, and fell to second place after a blowout loss. The Lions scored first when Matt Prater hit a 48-yard field goal in the first quarter. The Patriots then took the lead which they kept for the rest of the game when Tim Wright caught a 4-yard touchdown pass from Tom Brady near the end of the first quarter. The Lions responded with a 20-yard field goal in the second quarter. The Patriots then scored two touchdowns on a 3-yard run from LeGarrette Blount, then an 8-yard catch by Tim Wright. New England's Stephen Gostkowski then kicked a 35-yard field goal to make the score 24-6 at halftime. The only score of the third quarter was a Patriots 35 yard field goal. In the final quarter, the Lions scored their third field goal, this one from 49 yards out. The Patriots capped their large victory with a 1-yard touchdown run from LeGarrette Blount. 
 Question: Who scored the only points of the third quarter?

A: patriots
****
Q: Context: Alejandro Adem is a professor in the Department of Mathematics at the University of British Columbia since 2005 and the holder of a Canada Research Chair at UBC. 
 Question: What is Alejandro Adem's place of employment?

A: university of british columbia
****
Q: Context: The RTS,S/AS01(E) candidate malaria vaccine is being developed for immunisation of infants in Africa through the expanded programme on immunisation (EPI). 8 month follow-up data have been reported for safety and immunogenicity of RTS,S/AS01(E) when integrated into the EPI. We report extended follow-up to 19 months, including efficacy results. We did a randomised, open-label, phase 2 trial of safety and efficacy of the RTS,S/AS01(E) candidate malaria vaccine given with EPI vaccines between April 30, 2007, and Oct 7, 2009, in Ghana, Tanzania, and Gabon. Eligible children were 6-10 weeks of age at first vaccination, without serious acute or chronic illness. All children received the EPI diphtheria, tetanus, pertussis (inactivated whole-cell), and hepatitis-B vaccines, Haemophilus influenzae type b vaccine, and oral polio vaccine at study months 0, 1, and 2, and measles vaccine and yellow fever vaccines at study month 7. Participants were randomly assigned (1:1:1) to receive three doses of RTS,S/AS01(E) at 6, 10, and 14 weeks (0, 1, 2 month schedule) or at 6 weeks, 10 weeks, and 9 months (0, 2, 7 month schedule) or placebo. Randomisation was according to a predefined block list with a computer-generated randomisation code. Detection of serious adverse events and malaria was by passive case detection. Antibodies against Plasmodium falciparum circumsporozoite protein and HBsAg were monitored for 19 months. This study is registered with ClinicalTrials.gov, number NCT00436007. 511 children were enrolled. Serious adverse events occurred in 57 participants in the RTS,S/AS01(E) 0, 1, 2 month group (34%, 95% CI 27-41), 47 in the 0, 1, 7 month group (28%, 21-35), and 49 (29%, 22-36) in the control group; none were judged to be related to study vaccination. At month 19, anticircumsporozoite immune responses were significantly higher in the RTS,S/AS01(E) groups than in the control group. Vaccine efficacy for the 0, 1, 2 month schedule (2 weeks after dose three to month 19, site-adjusted according-to-protocol analysis) was 53% (95% CI 26-70; p=00012) against first malaria episodes and 59% (36-74; p=00001) against all malaria episodes. For the entire study period, (total vaccinated cohort) vaccine efficacy against all malaria episodes was higher with the 0, 1, 2 month schedule (57%, 95% CI 33-73; p=00002) than with the 0, 1, 7 month schedule (32% CI 16-45; p=00003). 1 year after dose three, vaccine efficacy against first malaria episodes was similar for both schedules (0, 1, 2 month group, 616% [95% CI 356-771], p<0001; 0, 1, 7 month group, 638% [404-780], p<0001, according-to-protocol cohort). Vaccine efficacy was consistent with the target put forward by the WHO-sponsored malaria vaccine technology roadmap for a first-generation malaria vaccine. The 0, 1, 2 month vaccine schedule has been selected for phase 3 candidate vaccine assessment. Program for Appropriate Technology in Health Malaria Vaccine Initiative; GlaxoSmithKline Biologicals. 
 Question: RTS S AS01 vaccine was developed to prevent which disease?

A:
malaria
****